ERCC1 Is a predictive biomarker for non-small cell lung cancer but is antibody-dependent

4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: To predict the efficacy of platinum-containing chemotherapy, ERCC1 expression levels were investigated. Studies have shown changes in the performance of anti-ERCC1 antibodies; therefore, predicting chemotherapy efficacy by immunohistochemical assessment of ERCC1 is controversial. Patients and Methods: Twenty-eight patients who received platinum-containing chemotherapy and underwent computed tomography evaluation 6-9 weeks after therapy initiation were retrospectively identified. The tumor samples were evaluated in 2012 and 2018 using the latest anti-ERCC1 antibodies available at those times. Results: In 2012, the ERCC1 H-score was significantly higher in patients with disease progression than in patients without disease progression (p=0.019). Although the same trend was shown in 2018, there were some inconsistent results between the 2012 and 2018 samples. Conclusion: Patients with tumors showing low ERCC1 expression had a better disease control rate on platinumcontaining chemotherapy. However, since the performance of the antibody changed over time, standardized technology to evaluate ERCC1 expression is needed.

References Powered by Scopus

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

13309Citations
N/AReaders
Get full text

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

3039Citations
N/AReaders
Get full text

Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer

2247Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy

25Citations
N/AReaders
Get full text

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer

5Citations
N/AReaders
Get full text

Multi-index comprehensive evaluation of the efficacy and response mechanism of immunotherapy in non-small cell lung cancer

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Okimoto, T., Tsubata, Y., Tanino, R., Nakao, M., Hotta, T., Hamaguchi, M., … Isobe, T. (2021). ERCC1 Is a predictive biomarker for non-small cell lung cancer but is antibody-dependent. Anticancer Research, 41(5), 2653–2660. https://doi.org/10.21873/ANTICANRES.15046

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

67%

Researcher 1

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

33%

Biochemistry, Genetics and Molecular Bi... 1

33%

Nursing and Health Professions 1

33%

Save time finding and organizing research with Mendeley

Sign up for free